BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kliemann DA, Tovo CV, da Veiga ABG, de Mattos AA, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol 2016; 22(40): 8910-8917 [PMID: 27833382 DOI: 10.3748/wjg.v22.i40.8910]
URL: https://www.wjgnet.com/1948-5182/full/v22/i40/8910.htm
Number Citing Articles
1
Sorin Dinu, Grațiela Țârdei, Emanoil Ceaușu, Simin Aysel Florescu, Laurențiu Micu, Alina Monica Ecobici, Mariana Mihăilă, Gabriela Oprișan. Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from RomaniaRevista Romana de Medicina de Laborator 2018; 26(4): 443 doi: 10.2478/rrlm-2018-0029
2
Figen Sarıgul, Murat Sayan, Ulku User, Nefise Oztoprak. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict RulesHepatitis Monthly 2019; (In Press) doi: 10.5812/hepatmon.62390
3
Zhenqiu Liu, Xianhua Mao, Jiaqi Wu, Kangkang Yu, Qin Yang, Chen Suo, Ming Lu, Li Jin, Tiejun Zhang, Xingdong Chen. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral AgentsClinical Gastroenterology and Hepatology 2021; 19(9): 1906 doi: 10.1016/j.cgh.2019.10.046
4
Desirée Lopes da Silva, Heloisa Marceliano Nunes, Pedro Eduardo Bonfim Freitas. Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Pará/BrazilVirus Research 2021; 292: 198251 doi: 10.1016/j.virusres.2020.198251
5
Abdulrazzaq N. Zghair, Nazar Sh. Mohammed, Sumayah Faruq Kasim. Gene Sequencing of Hepatitis C Virus Isolated from Patients with Liver DiseasesJournal of Pure and Applied Microbiology 2023; 17(2): 819 doi: 10.22207/JPAM.17.2.08
6
Alfredo P. Martínez, Andrés C.A. Culasso, Paula S. Pérez, Vanesa Romano, Rodolfo H. Campos, Ezequiel Ridruejo, Gabriel García, Federico A. Di Lello. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80KVirus Research 2017; 240: 140 doi: 10.1016/j.virusres.2017.08.006
7
Victor de Lédinghen, Clovis Lusivika‐Nzinga, Jean‐Pierre Bronowicki, Fabien Zoulim, Dominique Larrey, Sophie Metivier, Albert Tran, Patrick Marcellin, Didier Samuel, Olivier Chazouillères, Stephane Chevaliez, Celine Dorival, Hélène Fontaine, Jean‐Michel Pawlotsky, Fabrice Carrat, Stanislas Pol. Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohortJournal of Viral Hepatitis 2020; 27(10): 964 doi: 10.1111/jvh.13321
8
Ana Elisa de Figueiredo Miranda Mundim, Fernanda de Oliveira Feitosa de de Castro, Marina Brandão Braz Albuquerque, Cesar Augusto Sam Tiago Vilanova-Costa, Irmtraut Araci Hoffmann Pfrimer, Antonio Márcio Teodoro Cordeiro Silva. Major mutations in the NS3 gene region of hepatitis C virus related to the resistance to direct acting antiviral drugs: a systematic reviewVirusDisease 2020; 31(3): 220 doi: 10.1007/s13337-020-00616-9
9
Will Gelson, Graeme Alexander. Is elimination of hepatitis C from the UK by 2030 a realistic goal?British Medical Bulletin 2017; 123(1): 59 doi: 10.1093/bmb/ldx017
10
Zhe Jiao, Yuanyuan Yan, Yixi Chen, Gang Wang, Xiaowei Wang, Lisha Li, Mengfang Yang, Xiaoshuai Hu, Yilin Guo, Yuejun Shi, Guiqing Peng, Tom Gallagher. Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease InhibitorsJournal of Virology 2022; 96(17) doi: 10.1128/jvi.00907-22
11
Jianjun Gao, Chuanxia Ju. Research progress on the direct antiviral drugs for hepatitis C virusBioScience Trends 2017; 11(1): 41 doi: 10.5582/bst.2016.01266
12
Pooneh Rahimi, Heidar Sharafi, Golnaz Bahramali, FaridehSadat SajadianFard, Nafiseh Sadat Asadi, Seyed Moayed Alavian, Vahid Iranpur Mobarakeh, Seyedeh Zahra Moravej. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C InfectionFrontiers in Microbiology 2021; 11 doi: 10.3389/fmicb.2020.617375
13
Ahmed Emam, Khaled R. A. Abdellatif, Noha H. Amin, Khaled M. Elokely. HCV NS5B RdRp mutations and their effects on ligand binding affinityInternational Journal of Modelling and Simulation 2022; 42(3): 415 doi: 10.1080/02286203.2021.1923953
14
V A Malov, E A Ubeeva, I P Ubeeva, S M Nikolaev, K T Umbetova. Treatment of chronic viral hepatitis C with direct acting antiviral agent: reviewTerapevticheskii arkhiv 2019; 91(11): 86 doi: 10.26442/00403660.2019.11.000307
15
Philippe Halfon, Caroline Scholtès, Jacques Izopet, Sylvie Larrat, Pascale Trimoulet, Fabien Zoulim, Laurent Alric, Sophie Métivier, Vincent Leroy, Denis Ouzan, Victor De Lédinghen, Sofane Mohamed, Guillaume Pénaranda, Hacène Khiri, Marie-Ange Thélu, Anne Plauzolles, Laurent Chiche, Marc Bourlière, Florence Abravanel. Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life CohortAntiviral Therapy 2018; 23(4): 307 doi: 10.3851/IMP3184
16
Song Yang, Huichun Xing, Shenghu Feng, Wei Ju, Shunai Liu, Xiaomei Wang, Weini Ou, Jun Cheng, Calvin Q. Pan. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis CArchives of Virology 2018; 163(2): 467 doi: 10.1007/s00705-017-3640-6
17
Lei Dai, Yushen Du, Hangfei Qi, Christian D. Huber, Dongdong Chen, Tian-Hao Zhang, Nicholas C. Wu, Ergang Wang, James O. Lloyd-Smith, Ren Sun, Tiffany A. Reese. Quantifying the Evolutionary Constraints and Potential of Hepatitis C Virus NS5A ProteinmSystems 2021; 6(2) doi: 10.1128/mSystems.01111-20
18
Itzíar Carrasco, Ana Arias, Laura Benítez‐Gutiérrez, Gemma Lledó, Silvia Requena, Miriam Cuesta, Valentín Cuervas‐Mons, Carmen de Mendoza. Baseline NS5A resistance associated substitutions may impair DAA response in real‐world hepatitis C patientsJournal of Medical Virology 2018; 90(3): 532 doi: 10.1002/jmv.24971
19
Lucio Boglione, Simone Mornese Pinna, Tommaso Lupia, Giuseppe Cariti, Giovanni Di Perri1. Retreatment with Sofosbuvir/Velpatasvir in Cirrhotic Patients with Genotype-4 who Failed a Previous Interferon-Free Regimen: A Case SeriesAntiviral Therapy 2018; 23(6): 543 doi: 10.3851/IMP3226
20
Calvin Q. Pan, Benjamin C. Tiongson, Ke-Qin Hu, Steven-Huy B. Han, Myron Tong, Danny Chu, James Park, Tai Ping Lee, Kalyan Ram Bhamidimarri, Xiaoli Ma, Pei Ying Xiao, Smruti R. Mohanty, Dan Wang. Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis CJournal of Clinical Gastroenterology 2019; 53(2): 147 doi: 10.1097/MCG.0000000000001078
21
Gül R. Yilmaz, Christoph Boesecke, Carolynne Schwarze‐Zander, Jürgen K. Rockstroh. Hepatitis C reinfection with protease inhibitor‐resistant hepatitis C virus in an HIV‐coinfected MSMLiver International 2020; 40(1): 47 doi: 10.1111/liv.14275
22
Dong Xiao, Xing Dai, Hong Liu, Shuwen He, Zhi-Cai Shi, Steven W. Ludmerer, Fangbiao Li, Ravi Nargund, Anandan Palani. Multi-step parallel synthesis enabled optimization of benzofuran derivatives as pan-genotypic non-nucleoside inhibitors of HCV NS5BBioorganic & Medicinal Chemistry Letters 2020; 30(7): 127004 doi: 10.1016/j.bmcl.2020.127004
23
Radwa R. El-Tahan, Ahmed M. Ghoneim, Hosam Zaghloul. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patientsVirus Genes 2020; 56(5): 564 doi: 10.1007/s11262-020-01776-y